←
Mark Ball, MD, FACS1,467 posts
Mark Ball, MD, FACS avatar✓

Mark Ball, MD, FACS ✓

@markballmd

Urologic Oncologist at NCI | Assoc Prof & Fellowship APD | #kidneycancer #pheo surgery & translational genomics 🧬 Views mine

◷ Joined June 2010▧ 244 Photos and videos
DAVA Oncology avatar
⟳ Mark Ball, MD, FACS retweeted
DAVA Oncology@DAVAOnc·Nov 7

Dr. @markballmd of @theNCI reviews current approaches to papillary RCC, including PAPMET, KEYNOTE-B61 and phase 2 cabozantinib + nivolumab data, while highlighting molecular subtyping and MET-directed precision oncology as evolving strategies. CALYPSO: cRR was 32% overall and 53% in MET-driven papillary RCC; no new safety signals. #DAVAGU

Post attachmentPost attachmentPost attachmentPost attachment
DAVA Oncology avatar
⟳ Mark Ball, MD, FACS retweeted
DAVA Oncology@DAVAOnc·Nov 5

Starting Soon: Advances in HIF Inhibitors in Advanced RCC Moderator: Dr. Mark Ball @markballmd @theNCI The session will explore belzutifan data (LITESPARK-011/033), emerging HIF-2α therapies & novel combination strategies in RCC. #DAVAGU

Post attachment
HLRCC Foundation avatar
⟳ Mark Ball, MD, FACS retweeted
HLRCC Foundation@HLRCCFoundation·Nov 3

With HLRCC, finding kidney tumors early matters. Yearly kidney imaging from age 8, often MRI, is recommended for people with or at risk of HLRCC. Ask your doctor what's right for you. Thanks to @markballmd and NCI for their work. Specialists: hlrcc.org/hlrcc-map/ #HLRCC

Post attachment
DAVA Oncology avatar
⟳ Mark Ball, MD, FACS retweeted
DAVA Oncology@DAVAOnc·Nov 4

Surgery or belzutifan in VHL? Dr. @markballmd (@theNCI) weighs serial partial nephrectomy morbidity against LITESPARK-004 ORRs (RCC 67%, CNS HB 48%, pNET 91%) and discusses when tumorgrowth on belzutifan may warrant surgery. #DAVAGU

Post attachmentPost attachmentPost attachmentPost attachment
Enrique Grande avatar
⟳ Mark Ball, MD, FACS retweeted
Enrique Grande@drenriquegrande·Oct 30

⚡️ On @EUplatinum 25-yr prospective NCI cohort of sporadic bilateral multifocal papillary RCC (n=89). Growth was predominantly indolent (median 1.55 mm/yr). Metastases occurred only in patients whose largest tumor exceeded 3 cm. Repeat ipsilateral partial nephrectomy was associated with a decline in renal function. Findings are consistent with active surveillance for small renal masses and nephron-sparing surgery when intervention is needed. #KidneyCancer sciencedirect.com/science/ar…

Post attachment
Global Society of Rare Genitourinary Tumors avatar
⟳ Mark Ball, MD, FACS retweeted
Global Society of Rare Genitourinary Tumors@GTumors·Oct 29

🔬 What is the natural history of sporadic bilateral/multifocal papillary #RCC? A 25-year prospective @theNCI 📈 Median growth: only 1.55 mm/year ⚠️ Metastases occurred in 6.7% — exclusively when the largest tumor was >3 cm 💡 These data provide important benchmarks supporting active surveillance for appropriately selected small tumors and nephron-sparing approaches when intervention is needed. Congratulations to the authors for advancing our understanding of this uncommon clinical entity! 📖 Read here: doi.org/10.1016/j.euo.2026.0… @HFu_MD @markballmd @SandeepGurramMD @montypal @kidneycan

Post attachment
Hangcheng Fu, MD avatar
⟳ Mark Ball, MD, FACS retweeted
Hangcheng Fu, MD@HFu_MD·Oct 4

Also a big shout-out to the @theNCI Urologic Oncology (SUO) fellowship 🙌 The fellowship gives us a platform not just to sharpen our operating, but to rethink GU cancer as a biology and a disease process. It also trains us to make careful, multidisciplinary decisions for every patient. NCI is a remarkable place to learn to think as a surgeon-scientist. Our clinical year has been just as rewarding. We now rotate at Walter Reed, Sibley, GW, and MedStar Washington Hospital Center, which gives us broad exposure across the DC area. Interested Applicants feel free to DM with questions! @PeterPintoMD @markballmd @patmichael93 @ztonysu @Moh_AhmedMD @Anis_Assad10 @RubenBlachmanMD @SUO_YUO @UroOnc #SUO #YUO #UroSoMe

Hangcheng Fu, MD avatar
⟳ Mark Ball, MD, FACS retweeted
Hangcheng Fu, MD@HFu_MD·Aug 14

Grateful for the chance to work on this unique project and share our experience. Big shout-out to the @theNCI @SUO_YUO @UroOnc fellowship — outstanding mentors, co-fellows, supportive staff, and a great city. Doing science and having fun. 🙌 @markballmd

Post attachment
Hangcheng Fu, MD avatar
⟳ Mark Ball, MD, FACS retweeted
Hangcheng Fu, MD@HFu_MD·Aug 14

New paper out in @EurUrolOncol! 🧬 We present the largest prospective cohort of sporadic bilateral/multifocal papillary RCC (89 patients, 25 years at the NCI). Key findings: 📉 Slow, indolent growth (median 1.55 mm/yr) 🎯 No metastases when largest tumor <3cm 🔬 Low metastatic rate overall (6.7%) 🩺 Repeat ipsilateral partial nephrectomy = biggest hit to kidney function Supports active surveillance for small renal masses + nephron-sparing surgery when intervention is needed. @markballmd @RubenBlachmanMD @MillanBraden @patmichael93 Natural History, Tumor Growth Kinetics, and Renal Functional Outcomes... sciencedirect.com/science/ar…

Mark Ball, MD, FACS avatar
Mark Ball, MD, FACS@markballmd·Aug 14

Thanks for sharing. Proud to finally show data to support the practice we have followed for a long time. @SUO_YUO fellow @HFu_MD put this together. Even when surgery is the the next step, my first ? is what life events do you have coming up - weddings, trips, etc. SRMs ≠ emergencies. @EurUrolOncol

Mark Ball, MD, FACS avatar
Mark Ball, MD, FACS@markballmd·Jul 7

If pathology influences how we operate, shouldn't we know it before or during surgery? Renal mass biopsy remains underutilized. We explored whether AI can predict final pathology from intraoperative gross tumor images. Early results are encouraging, and we're just getting started. Led by #MilanPatel. sciencedirect.com/science/ar…